The antihypertension drug which achieved sales of about 2 bn US-$ in 2012 but is now off-patent may have been advertised by “inappropriate expressions”. An investigation by the Ministry of Health, Labour and Welfare is underway.
China Bio news release, March 7, 2014
Takeda under inquiry about improper marketing of its blockbuster Blopress